Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dosimetric and radiobiological analyses of a de-escalation strategy for elective nodal regions in human papillomavirus-associated oropharyngeal cancer.
Tomita N, Hayashi N, Mizuno T, Kitagawa Y, Yasui K, Saito Y, Sudo S, Takano S, Kita N, Torii A, Niwa M, Okazaki D, Takaoka T, Kawakita D, Iwasaki S, Hiwatashi A. Tomita N, et al. Among authors: iwasaki s. Tech Innov Patient Support Radiat Oncol. 2023 Oct 13;28:100221. doi: 10.1016/j.tipsro.2023.100221. eCollection 2023 Dec. Tech Innov Patient Support Radiat Oncol. 2023. PMID: 37886016 Free PMC article.
Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.
Takano G, Esaki S, Goshima F, Enomoto A, Hatano Y, Ozaki H, Watanabe T, Sato Y, Kawakita D, Murakami S, Murata T, Nishiyama Y, Iwasaki S, Kimura H. Takano G, et al. Among authors: iwasaki s. Mol Ther Oncolytics. 2020 Dec 19;20:220-227. doi: 10.1016/j.omto.2020.12.007. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2020. PMID: 33665360 Free PMC article.
Long-term efficacy of weekly paclitaxel therapy in unresectable primary squamous cell carcinoma of the thyroid.
Iwaki S, Kawakita D, Sawabe M, Matoba T, Takano G, Oguri K, Murashima A, Minohara K, Tanaka N, Tsuge H, Imaizumi S, Matsumura A, Masaki A, Murase T, Ogawa M, Iwasaki S. Iwaki S, et al. Among authors: iwasaki s. Auris Nasus Larynx. 2022 Dec;49(6):1083-1087. doi: 10.1016/j.anl.2021.06.005. Epub 2021 Jul 3. Auris Nasus Larynx. 2022. PMID: 34226099
Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab.
Minohara K, Matoba T, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Hojo W, Matsumura A, Ozaki S, Ozawa T, Harata I, Tanaka N, Maseki S, Tsuge H, Imaizumi S, Mitsuya S, Moribe K, Esaki S, Iwasaki S. Minohara K, et al. Among authors: iwasaki s. Sci Rep. 2021 Aug 20;11(1):16992. doi: 10.1038/s41598-021-96538-7. Sci Rep. 2021. PMID: 34417539 Free PMC article.
Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors.
Matoba T, Minohara K, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Tsuge H, Tanaka N, Imaizumi S, Hojo W, Matsumura A, Tsukamoto K, Esaki S, Iwasaki S. Matoba T, et al. Among authors: iwasaki s. Sci Rep. 2022 Aug 22;12(1):14319. doi: 10.1038/s41598-022-18611-z. Sci Rep. 2022. PMID: 35996017 Free PMC article.
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: iwasaki s. Cancer Med. 2023 Dec;12(24):21666-21679. doi: 10.1002/cam4.6724. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37986680 Free PMC article.
1,372 results